Prestige Consumer Healthcare (NYSE:PBH) Updates FY 2026 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 4.540-4.540 for the period, compared to the consensus EPS estimate of 4.550. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Prestige Consumer Healthcare Trading Up 1.4%

NYSE:PBH opened at $66.48 on Friday. The company has a quick ratio of 2.51, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The company has a market cap of $3.20 billion, a PE ratio of 17.59, a P/E/G ratio of 2.06 and a beta of 0.43. Prestige Consumer Healthcare has a 52 week low of $57.25 and a 52 week high of $90.04. The business’s 50 day moving average is $63.19 and its two-hundred day moving average is $64.06.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. During the same period last year, the firm posted $1.22 EPS. The business’s quarterly revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Oppenheimer dropped their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Finally, Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $80.60.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the sale, the vice president owned 42,329 shares of the company’s stock, valued at approximately $2,539,740. This trade represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.40% of the stock is owned by insiders.

Key Stories Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Management highlighted progress restoring Clear Eyes supply and said availability is improving, which supports a rebound in that brand’s sales going forward. Prestige Consumer Healthcare narrows fiscal 2026 revenue outlook to $1.1B while advancing Clear Eyes supply recovery
• Positive Sentiment: The company narrowed and finalized its fiscal‑2026 revenue outlook to about $1.1 billion, which reduces uncertainty around full‑year expectations and may reassure investors. Prestige Consumer Healthcare Q3 revenue tops estimates, narrows guidance
• Neutral Sentiment: Management posted the full slide deck and call transcript; these provide detail on segment trends, margins and working‑capital dynamics for investors doing deeper diligence. Q3 2026 Earnings Call Transcript
• Negative Sentiment: Q3 results showed a small EPS miss: $1.14 reported vs. ~$1.16 consensus, and revenue of ~$283.4M was down roughly 2.4% year‑over‑year—factors that are short‑term headwinds for the stock. Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
• Negative Sentiment: Fiscal‑2026 EPS guidance was set at 4.54 (company’s figure), essentially flat-to-slightly below some sell‑side consensus (~4.55), leaving limited upside in near‑term estimates. Press release: Third Quarter and Year-to-Date Fiscal 2026 Results

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in shares of Prestige Consumer Healthcare by 19.1% in the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after acquiring an additional 115,459 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 15.7% in the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock worth $39,807,000 after buying an additional 86,373 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Prestige Consumer Healthcare by 12.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 553,407 shares of the company’s stock valued at $44,190,000 after acquiring an additional 63,168 shares during the period. Goldman Sachs Group Inc. raised its stake in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after acquiring an additional 120,965 shares during the period. Finally, UBS Group AG boosted its stake in Prestige Consumer Healthcare by 9.6% in the 3rd quarter. UBS Group AG now owns 420,465 shares of the company’s stock worth $26,237,000 after purchasing an additional 36,770 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).